Chloroquine

Details About Generic Salt ::  Chloroquine 

Main Medicine Class:: Anti Infectives   Sub Medicine Class ::  Anti Malarials

12D. ANTI-RHEUMATIC DRUGS (DMARDS) in 12. MUSCULOSKELETAL DISORDERS & PAIN
CHLOROQUINE
4-AMINOQUINOLINE | ANTI-MALARIAL, ANTI-RHEUMATIC
also comes under 13J. Anti-Malarials in 13. Anti-Infectives,  
PK: A: Rapid & complete D: Extensive M: Hepatic E: Urine

Indications & Dose: HEPATIC AMOEBIASIS PO Adult 600mg/day as base for 2 days, then 300mg/day 2-3 wk Child 6mg/kg/day, max 300mg/day | LIGHT-SENSITIVE SKIN ERUPTIONS PO Adult 150-300mg/day as base Child 3mg/kg | MALARIA Acute PO Adult 1g (600mg base) on day 1, followed by 500mg (300 mg base) 6-8h later, followed by 500mg (300mg base) on days 2 & 3 Child 16.6mg/kg (10mg/kg base) on day 1, max 1g (600mg base), followed by 8.3mg/kg (5mg/kg base or 300mg base/dose), max 500mg/dose (300mg base/dose) 6, 24 & 36h after first dose | Complicated/Severe IV General 25mg/kg given in several inf over 30-32h, if patient is able to tolerate oral therapy then stop IV regimen & start oral therapy | RHEUMATOID ARTHRITIS PO Adult 150mg/day given as base, max 2.5mg/kg/day. Discontinue if there is no improvement after 6 month Child 3mg/kg/day. Discontinue if there is no improvement after 6 month | SUPPRESSION/PROPHYLAXIS OF MALARIA PO Adult 500mg/wk (300mg base) on the same day each wk, begin 2 wk prior to exposure & continue for 4 wk after exposure. If suppressive therapy is not begun prior to exposure, double the initial loading dose to 1g (600 mg base) in 2 divided doses 6h apart, followed by usual dosage regimen Child 8.3mg/kg/wk (5mg/kg base) on the same day each wk (not to exceed 500mg/dose [300mg base/dose]), begin 1-2 wk prior to exposure & continue for 4 wk after exposure. If suppressive therapy is not begun prior to exposure, double the initial loading dose to 16.6mg/kg (10mg/kg base), max 1g (600mg base) in 2 divided doses 6h apart followed by usual dosage regimen | SYSTEMIC LUPUS ERYTHEMATOSUS PO Adult 150mg/day as base, max 2.5mg/kg Child 3mg/kg/day

Contra: Hypersensitivity, retinal/visual field changes

Precautions: Patients with G6PD deficiency, porphyria, psoriasis, history of seizure disorder, pre-existing auditory damage, myasthenia gravis, hepatic impairment, concurrent use of QTc prolonging agents, history of pre-existing auditory damage, severe GI disorders

ADR: Serious: Anaphylaxis, angioedema, cardiomyopathy, Torsade de pointes, ECG changes, hypotension, SJS, TEN, blurred vision, tinnitus, visual field defects, corneal opacities, neuromyopathy, proximal muscle atrophy, retinopathy, depression of deep tendon reflexes, polyneuritis, nerve deafness, blood disorders, Others: Agitation, anxiety, confusion, delirium, depression, hallucinations, headache, insomnia, alopecia, abdominal cramps, erythema multiforme, anorexia, diarrhea, nausea, vomiting

DDI: Serious Antacids/Ampicillin absorption reduced, Vaccine, Cholera/Vaccine, Rabies antibody response is reduced, Antihistamines increases drug levels, Drugs that prolong QT interval/Amiodarone increases risk of torsade de pointes, Antidiabetics leads to hypoglycemia, Neuromuscular blockers leads to respiratory depression, apnea, Metoprolol/Chlorpromazine/Paracetamol levels increases, Corticosteroids/Ciprofloxacin levels reduces, Ciclosporin levels rises & leads to nephrotoxicity

Diet: With food

Monitor: CBC, neuromuscular function, fundoscopic and visual field examination, ophthalmic exams, visual acuity during therapy